Media Doctor Canada
Follow us on Twitter








"Vaccine doubles survival of deadly cancer"

Globe and Mail

Source: Globe and Mail

Published: 02 Jun 2022

Category: Other

Rating: (1½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

CHICAGO - A cancer vaccine more than doubled the survival time of people with the most common and deadly type of brain tumour, U.S. researchers said on Monday.

The vaccine, made by Avant Immunotherapeutics Inc and licensed by drug giant Pfizer Inc., enlists the help of the immune system to attack the tumour.

Researchers treated 23 patients with a type of brain tumor called glioblastoma multiforme. They have lived, on average, 33 months, said Dr. John Sampson of Duke University, who presented the study at a meeting of the American Society of Clinical Oncology in Chicago. "That is almost unheard of," Dr. Sampson said in an interview....

The original article can be found at:

The original article can found in the Media Doctor archives.

how did it rate? (more information)

Criteria Rating
Total Score 3 of 10
Availability of Treatment Not Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Not Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Not Satisfactory (?)
Quantification of Benefits of Treatment Satisfactory (?)
Harms of Treatment Not Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of harms of treatment Not Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

This study of a cancer vaccine for a type of brain tumor called glioblastoma multiforme was conducted in 23 patients. Survival is described as 33 months vs. 14 months (vaccine vs. placebo) except given that it's such a small trial we are not sure if those results are statistically significant. Furthermore there is no discussion of the potential harms of the treatment, the availability of the treatment, its cost or availability or if the quoted researchers have any financial conflicts of interest. These types of stories, based on very preliminary research need to be supplied with the appropriate caveats so patients with this condition do not develop unrealistic expectations of the treatment's potential effect.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada